KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Non-cash Items (2016 - 2025)

CRISPR Therapeutics AG's Non-cash Items history spans 11 years, with the latest figure at $42.3 million for Q4 2025.

  • For Q4 2025, Non-cash Items rose 200.85% year-over-year to $42.3 million; the TTM value through Dec 2025 reached $42.3 million, up 200.85%, while the annual FY2025 figure was $42.3 million, 200.85% up from the prior year.
  • Non-cash Items for Q4 2025 was $42.3 million at CRISPR Therapeutics AG, up from $4.6 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $219.1 million in Q4 2021 and bottomed at $4.4 million in Q3 2021.
  • The 5-year median for Non-cash Items is $9.5 million (2024), against an average of $59.8 million.
  • The largest annual shift saw Non-cash Items soared 5074.36% in 2021 before it crashed 97.51% in 2022.
  • A 5-year view of Non-cash Items shows it stood at $219.1 million in 2021, then tumbled by 85.34% to $32.1 million in 2022, then soared by 260.03% to $115.7 million in 2023, then tumbled by 87.85% to $14.0 million in 2024, then surged by 200.85% to $42.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Non-cash Items are $42.3 million (Q4 2025), $4.6 million (Q3 2025), and $5.0 million (Q2 2025).